MYOINOSITOL INCORPORATION INTO LYMPHOCYTES OF CHRONIC-RENAL-FAILURE PATIENTS IS IMPAIRED

Incorporation of myo-[2-H-3]-inositol into peripheral blood mononuclea r cells (PBMNC) and T-cell enriched lymphocytes was evaluated in in-vi tro experiments in chronic renal failure (CRF) patients and healthy su bjects. Incorporation of myo-[2-H-3]-inositol into the cells of CRF pa tients on conservative and haemodialysis treatment was found to be imp aired in comparison with that observed in normal cells. Following PHA stimulation of the cells of CRF patients myo-[2-H-3]-inositol incorpor ation decreased even further, while it increased in normal cells. Five -hour haemodialysis session significantly depressed myoinositol incorp oration into PBMNC, while its incorporation into T-cell enriched lymph ocytes remained unaffected. Myoinositol incorporation into PBMNC and T -cell enriched lymphocytes was inhibited by prostaglandins and leukotr ienes and was inversely related to the extent of pertussis toxin-sensi tive G protein activation. Reduced myoinositol incorporation into urae mic PHA-stimulated PBMNC may depend at least in part on their enhanced PGE(2) and LTB(4) release accompanied by increased intracellular cAMP production. In CRF impaired myoinositol incorporation into immune cel ls may prove the disarrangement in the early events of transmembrane s ignal transduction, which may share the responsibility for the cell-me diated immune defect in these patients.